Mammography firm TransScan Research and Development has received clearance from the Food and Drug Administration for a premarket approval supplement for its TS-2000 electrical impedance breast scanning system that covers improvements in the unit’s
Mammography firm TransScan Research and Development has received clearance from the Food and Drug Administration for a premarket approval supplement for its TS-2000 electrical impedance breast scanning system that covers improvements in the units design and operation. The Ramsey, NJ, firm announced the news along with Siemens Medical Systems of Iselin, NJ, with which it signed a marketing agreement last December (SCAN 1/7/99).
A hand-held device that measures electrical impedance in breast tissue, TS-2000 includes a ground-electrode cylinder that patients hold as it transmits a low-voltage electrical signal through the body. A probe placed on the breast and moved across the skin measures changes in the signal. In real-time, the probe produces images on a computer screen that reveal differences in the electrical impedance between malignant tumor tissue and normal tissue.
The unit was initially cleared by the FDA in April for use as an adjunct to mammography for follow-up exams in patients with equivocal mammograms (SCAN 4/28/99). TransScan hopes that the cleared PMA supplement will pave the way for the unit to be used for other types of cancer.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.